EMAIL THIS PAGE TO A FRIEND

Scientific reports

Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4.


PMID 26596901

Abstract

Inhibition of cancer-promoting kinases is an established therapeutic strategy for the treatment of many cancers, although resistance to kinase inhibitors is common. One way to overcome resistance is to target orthogonal cancer-promoting pathways. Bromo and Extra-Terminal (BET) domain proteins, which belong to the family of epigenetic readers, have recently emerged as promising therapeutic targets in multiple cancers. The development of multitarget drugs that inhibit kinase and BET proteins therefore may be a promising strategy to overcome tumor resistance and prolong therapeutic efficacy in the clinic. We developed a general computational screening approach to identify novel dual kinase/bromodomain inhibitors from millions of commercially available small molecules. Our method integrated machine learning using big datasets of kinase inhibitors and structure-based drug design. Here we describe the computational methodology, including validation and characterization of our models and their application and integration into a scalable virtual screening pipeline. We screened over 6 million commercially available compounds and selected 24 for testing in BRD4 and EGFR biochemical assays. We identified several novel BRD4 inhibitors, among them a first in class dual EGFR-BRD4 inhibitor. Our studies suggest that this computational screening approach may be broadly applicable for identifying dual kinase/BET inhibitors with potential for treating various cancers.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

226947
3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate, 98%
C32H58N2O7S · xH2O
C3023
CHAPS hydrate, ≥98% (HPLC)
C32H58N2O7S · xH2O
RDD002
HEPES, anhydrous, free-flowing, Redi-Dri, ≥99.5%
C8H18N2O4S
H3375
HEPES, ≥99.5% (titration)
C8H18N2O4S
H4034
HEPES, BioPerformance Certified, ≥99.5% (titration), cell culture tested
C8H18N2O4S
PHG0001
HEPES, PharmaGrade, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production, suitable for cell culture
C8H18N2O4S
RES6003H-B7
HEPES, PharmaGrade, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production, suitable for cell culture
C8H18N2O4S
H7523
HEPES, BioXtra, pH 5.0-6.5 (1 M in H2O), ≥99.5% (titration)
C8H18N2O4S
H6147
HEPES, BioXtra, suitable for mouse embryo cell culture, ≥99.5% (titration)
C8H18N2O4S
54457
HEPES, BioUltra, for molecular biology, ≥99.5% (T)
C8H18N2O4S
83264
HEPES buffer solution, 1 M in H2O
C8H18N2O4S
P5811
Phosphoric acid, BioReagent, suitable for insect cell culture, 85%
H3O4P
466123
Phosphoric acid, crystalline, ≥99.999% trace metals basis
H3O4P
452289
Phosphoric acid, ≥85 wt. % in H2O, ≥99.999% trace metals basis
H3O4P
345245
Phosphoric acid, 85 wt. % in H2O, 99.99% trace metals basis
H3O4P
79617
Phosphoric acid, BioUltra, ≥85% (T)
H3O4P
04102
Phosphoric acid, puriss., ≥99%
H3O4P
40278
Phosphoric acid, semiconductor grade MOS PURANAL (Honeywell 17938), ≥85%
H3O4P
40266
Phosphoric acid, semiconductor grade PURANAL (Honeywell 17861), ≥85%
H3O4P
612162
Phosphoric acid solution, NMR reference standard, 85% in D2O (99.9 atom % D), NMR tube size 4.2 mm × 8 in. , WGS-5BL Coaxial NMR tube
H3O4P
699608
Phosphoric acid solution, NMR reference standard, 85% in D2O (99.9 atom % D), NMR tube size 3 mm × 8 in.
H3O4P
698822
Phosphoric acid solution, NMR reference standard, 85% in D2O (99.9 atom % D), NMR tube size 5 mm × 8 in.
H3O4P
W290017
Phosphoric acid solution, 85 wt. % in H2O, FCC, FG
H3O4P
609781
Phosphoric acid-16O4 solution, 70 wt. % in D2O, 99.9 atom % 16O
H316O4P